{"url_path":"/sec/plyx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","accession_number":"0001213900-26-056973","cik":"0002075320","ticker":"PLYX","issuer_name":"Polaryx Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","primary_entity_key":"0002075320","primary_entity_name":"Polaryx Therapeutics, Inc."},"word_count":44,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\nTrading Plans\n\n \n\nDuring the quarter ended March 31, 2026, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).\n\n \n\n28"}